Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 3/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080736 | 0.86 | NQO2 (0.45) | PGRNQO2CDYL2CDYLIDO1 | |
| SCHEMBL28975294 | 0.78 | PGR (0.56) | PGRNQO2CDYL2CDYLIDO1 | |
| SCHEMBL2320598 | 0.78 | PGR (0.56) | PGRNQO2CDYL2CDYLIDO1 | |
| SCHEMBL9773884 | 0.78 | POLB (0.50) | PGRCDYL2CDYLIDO1GAA | |
| SCHEMBL13698108 | 0.77 | SMN1; SMN2 (0.37) | NQO2IDO1GAATHRBMAPT | |
| SCHEMBL24019919 | 0.76 | PGR (0.57) | PGRNQO2IDO1GAATP53 | |
| SCHEMBL2988866 | 0.76 | PGR (0.57) | PGRNQO2IDO1GAATP53 | |
| SCHEMBL2989569 | 0.75 | TP53 (0.62) | PGRNQO2GAATP53MAPT | |
| SCHEMBL24754591 | 0.75 | PGR (0.72) | PGRNQO2CDYL2CDYLTP53 | |
| SCHEMBL2986303 | 0.75 | PGR (0.72) | PGRNQO2CDYL2CDYLTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | PGR 1338/4885NQO2 2738/4885CDYL2 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.